Immunotherapeutic approaches have demonstrated strong potential to overcome the limitations of conventional cancer therapy, but only a few of them were able to demonstrate efficacy in clinical trials.  TRION Pharma, however, has already established clinical proof of concept with its trifunctional antibodies called Triomab®. While initial clinical development focused on advanced tumor stages, the application is now being expanded to address minimal residual disease. It has already been demonstrated that Triomab® antibodies can be safely administered during surgery immediately after tumor resection. The goal is to find and destroy remaining tumor cells and thus prevent cancer relapse.